Literature DB >> 21485716

Chronic pelvic pain syndromes--traditional and novel therapies: part I surgical therapy.

J H Check.   

Abstract

PURPOSE: To describe the role of various surgical therapies for the relief of pelvic pain.
METHODS: The latest studies involving surgical therapies for relief of pelvic pain are reviewed and the pros and cons are discussed.
RESULTS: Laparoscopic removal of endometriotic implants should be performed if the surgical procedure is being performed for diagnostic purposes. Laparoscopic utersacral nerve ablation of endometriotic implants and presacral neurectomy may provide additional relief but require greater surgical skills and have significant risks, especially bleeding. There still is a role for complete hysterectomy usually with bilateral salpingo-oophorectomy.
CONCLUSIONS: Recurrence rates following surgery relegate surgical procedures behind medical therapy, i.e., to be used only if medical therapy is failing. Not all pelvic pain is related to endometriosis. Some novel concepts as to common mechanisms involved in a large percentage of these pelvic pain syndromes leading to some novel highly effective medical therapies will be discussed in part II.

Entities:  

Mesh:

Year:  2011        PMID: 21485716

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  2 in total

1.  Diffusion tensor imaging and tractography to evaluate sacral nerve root abnormalities in endometriosis-related pain: a pilot study.

Authors:  L Manganaro; M G Porpora; V Vinci; S Bernardo; P Lodise; P Sollazzo; M E Sergi; M Saldari; G Pace; G Vittori; C Catalano; P Pantano
Journal:  Eur Radiol       Date:  2013-08-28       Impact factor: 5.315

2.  Macrophage migration inhibitory factor antagonist blocks the development of endometriosis in vivo.

Authors:  Khaled Khoufache; Sylvie Bazin; Karine Girard; Julie Guillemette; Marie-Christine Roy; Jean-Pierre Verreault; Yousef Al-Abed; Warren Foster; Ali Akoum
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.